Monthly Oncology Tumor Boards: A Multidisciplinary Approach to Individualized Patient Care - Head and Neck Cancer

August 19, 2020

Head and Neck Cancer: Optimal Multidisciplinary Management
Health-related quality of life issues are paramount in head and neck (H&N) cancers, since these tumors affect basic physiologic functions (i.e., the ability to chew, swallow, and breathe), the senses (i.e., taste, smell, hearing), and uniquely human characteristics (i.e., appearance, voice). Despite the ambiguities of PD-L1 testing and definitions, PD-L1 expression may be associated with better outcomes from treatment with immunotherapy for recurrent or metastatic squamous cell H&N cancer (i.e., greater likelihood of response to pembrolizumab and greater survival benefit in response to nivolumab). Emerging data show that cetuximab combined with radiation therapy is not an optimal de-escalation strategy for patients with p16-positive oropharyngeal cancer.

Target Audience

This educational program is designed to meet the educational needs of physicians/oncologists, nurse practitioners, nurses, physician assistants, pharmacists, and other health care professionals who manage patients with cancer.

Learning Objectives

Following this activity, participants should be able to:

  • Compare and contrast optimal treatment options for patients with locoregionally advanced head and neck cancer.
  • Review the evidence supporting immunotherapy options for patients with recurrent or metastatic head and neck cancer.
  • Recognize the impact of head and neck tumors on quality of life and associated interventions for managing and preventing disease- and treatment-related sequelae.
Additional information
Supporters: 

This activity is supported by educational grants from:

  • AstraZeneca
  • Clovis Oncology, Inc.
  • Daiichi Sankyo, Inc.
  • GlaxoSmithKline
  • Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC
  • Lilly
  • Novartis
  • Puma Biotechnology
  • Seattle Genetics, Inc.
  • Taiho Oncology, Inc.

This activity is supported by independent educational grants from:

  • Astellas and Pfizer, Inc.
  • Merck  & Co., Inc.

This activity is supported by independent medical education grants from:

  • Bristol Myers Squibb
  • Sanofi Genzyme

This educational activity is supported by medical education grants from:

  • Exelixis, Inc.
  • Karyopharm Therapeutics
Course summary
Available credit: 
  • 1.00 AAPA Category 1 CME credit
  • 1.00 ACPE contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC contact hours
  • 1.00 CCM clock hours
  • 1.00 Participation
Course opens: 
06/17/2020
Course expires: 
10/25/2020
Event starts: 
08/19/2020 - 1:15pm EDT
Event ends: 
08/19/2020 - 2:15pm EDT
Cost:
$0.00
Part of: 
Monthly Oncology Tumor Boards: A Multidisciplinary Approach to Individualized Patient Care (June 2020 - May 2021)
Add to calendar: 

Danette Birkhimer, MS, APRN-CNS, AOCNS
The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute

Dukagjin M. Blakaj, MD, PhD
The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute

Marcelo R. Bonomi, MD
The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute

Matthew Old, MD
The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute

 

NCCN Medical Education Disclosure Policy
It is the policy of NCCN that every 12 months, all faculty, moderators, activity planners and all internal planning staff participating in NCCN continuing education activities are expected to disclose any financial relationships with a commercial interest as defined by the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support. In addition, all faculty presentations have been reviewed for adherence to the ACCME’s Standards for Commercial Support (the provider develops activities/educational interventions independent of commercial interests [SCS 1, 2 and 6] by experts on the topics). 

Per the ACCME Standards for Commercial Support, individuals who do not disclose relevant financial relationships will be disqualified from involvement in the CE activity as a content developer, planner, or presenter. A complete list of individuals’ relationships with external entities is available upon request.

Definitions  
NCCN continuing education considers financial relationships to create a “conflict of interest” when an individual has both a financial relationship with a commercial interest and the opportunity to affect CE content about the products or services of a commercial interest with which he/she and/or a spouse or partner has a financial relationship.

NCCN continuing education considers “relevant financial relationships” as financial relationships in any amount occurring within the past 12 months that create a conflict of interest. NCCN does not set a minimal dollar amount for relationships to be significant. Inherent in any amount is the incentive to maintain or increase the value of the relationship. 

Faculty Disclaimers  
All faculty for this continuing education activity are competent in the subject matter and qualified by experience, training, and/or preparation for the tasks and methods of delivery.

Faculty presentations may include discussion of off-label use. Faculty will disclose that the use in question is not currently approved by the FDA per the product labeling.

Faculty Disclosures
The faculty listed below discloses no relevant financial relationships:
Danette Birkhimer, MS, APRN-CNS, AOCNS
Dukagjin M. Blakaj, MD, PhD
Marcelo R. Bonomi, MD
Matthew Old, MD

NCCN Staff Disclosures
The NCCN Activity Planning staff listed below discloses no relevant financial relationships:
Melissa Esplen; Mark A. Geisler; Kristina M. Gregory, RN, MSN, OCN; Kristin Kline Hasson; Rose Joyce; Karen Kanefield; Lisa Perfidio, MS; Shannon Ryan, CMP; Kathy Ann Smith, CHCP; Sarah Weinstein

The NCCN Clinical staff listed below discloses no relevant financial relationships:
Susan Darlow, PhD

In support of improving patient care, National Comprehensive Cancer Network (NCCN) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physicians
NCCN designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses
NCCN designates this educational activity for a maximum of 1.0 contact hour.

Pharmacists
NCCN designates this knowledge-based continuing education activity for 1.0 contact hour (0.10 CEUs) of continuing education credit. UAN: JA4008196-0000-20-073-L01-P

Physician Assistants 
NCCN has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.0 AAPA Category 1 CME credit. PAs should only claim credit commensurate with the extent of their participation.

Case Managers
This program has been pre-approved by The Commission for Case Manager Certification to provide continuing education credit to CCM® board certified case managers. The course is approved for 1.0 CE contact hour. Activity Code: I00042994; Approval #: 200137907

Available Credit

  • 1.00 AAPA Category 1 CME credit
  • 1.00 ACPE contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC contact hours
  • 1.00 CCM clock hours
  • 1.00 Participation

Price

Cost:
$0.00
Please login or register to take this course.

Click the Take Course button to register for this live webinar.

This webinar was presented live one time only on Wednesday, August 19, 2020, from 1:15 - 2:15 PM EDT.

Required Hardware/software

To complete this activity, users will need:

  • A device with an Internet connection and sound playback capability
    • One of the two latest versions of Google Chrome, Mozilla Firefox, or Safari
    • Internet Explorer is no longer supported
  • Adobe Reader or other PDF reader software for certificate viewing/printing